











Intravitreal versus sub-Tenon triamcinolone 


















Intravitreal versus sub-Tenon triamcinolone 















Submitted in partial fulfilment of the requirements for the degree 
of 
 
Masters of Medicine 
 
In the 
Department of Ophthalmology 
Nelson R. Mandela School of Medicine 










Purpose: To compare the safety and efficacy of intravitreal (IVT) and sub-
Tenon (ST) triamcinolone acetonide for the treatment of refractory diffuse 
diabetic macular oedema. 
 
 
Method: 29 eyes of 22 patients with long-standing, diffuse diabetic 
macular oedema refractory to argon laser treatment were randomly assigned 
to a single 4mg injection of IVT triamcinolone acetonide or a 40mg sub-
Tenon injection. Patients were subsequently monitored for six to nine 
months. Outcome measures were visual acuity, intraocular pressure, macular 
thickness on optical coherence tomography and adverse effects. 
 
 
Results:  There was no significant improvement in visual acuity in either 
group. A transient decrease in macular thickness was found in the IVT group 
but not in the ST group. There were no significant adverse effects apart from 
a mild to moderate intra-ocular pressure rise found more frequently in the 
IVT group.  
 
 
Conclusion: IVT and ST triamcinolone acetonide injections for refractory 
diffuse diabetic macular oedema appear relatively safe and well-tolerated. 
IVT injection produces a significant temporary decrease in macular 
thickness in patients with long-standing diffuse diabetic macular oedema 
while ST injection does not. Neither intervention was shown to significantly 
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Introduction and literature review 
 
The greater Durban metropolitan region of KwaZulu-Natal has a large 
diabetic population with a full spectrum of diabetic-related eye disease, 
posing a considerable public health problem. Macular oedema is a common 
ocular complication of diabetes worldwide, affecting 29% of diabetics with 
disease duration of 20 years or more.
1
 It remains the most common reason 
for loss of vision in diabetics. The treatment of diffuse diabetic macular 
oedema is at present limited and often unsatisfactory, leaving many patients 
severely debilitated with compromised macular vision.  
 
The current standard of care in the treatment of diffuse diabetic macular 
oedema is the use of argon laser grid photocoagulation. The Early Treatment 
Diabetic Retinopathy Study (ETDRS - 1985) showed the benefit of focal 
laser treatment for clinically significant macular oedema, which reduced the 
risk of further visual loss by 50%.
2
 However only 17% of patients were 
shown to have an improvement in vision with laser treatment and only 3% 






had an improvement of 3 or more Snellen chart lines. Diffuse diabetic 
macular oedema is notoriously difficult to treat and studies have shown 
disappointing results from grid argon laser treatment.
3
 The experience of the 
ophthalmology department of the University of KwaZulu-Natal reflects 
published findings - one of satisfactory results with focal argon laser 
treatment for focal clinically significant macular oedema but disappointing 
results with grid laser in diffuse oedema. Diffuse oedema and visual acuity 
seldom improve despite laser treatment and many patients are considered to 
have refractory disease. 
 
Figure 1 - Diabetic maculopathy with clinically significant macular oedema. 





Figure 2 – Fluorescein angiogram - diffuse diabetic macular oedema and previous argon 
laser retinal scarring. 
 
 
Figure 3 – Fluorescein angiogram - chronic diffuse cystoid diabetic macular oedema. 
 9 
It is in this context that alternative treatments to laser have been sought. 
Intravitreal crystalline corticosteroid suspension in the form of triamcinolone 
acetonide (TA) has been investigated for the treatment of diabetic macular 
oedema refractory to conventional therapy at several ophthalmology centres 
worldwide.
4,5,6
 Its use proliferated worldwide after Martidis, Duker et al 
(2002) first published promising results of its use in the treatment of diffuse 
diabetic macular oedema. They injected 4mg of triamcinolone intravitreally 
in sixteen eyes with clinically significant diabetic macular oedema that 
failed to respond to two previous sessions of laser photocoagulation. They 
found a significant mean improvement in visual acuity of 2.4 Snellen lines at 
the 1 month follow up, 2.4 lines at 3 months and 1.3 lines at 6 months. The 
central macular thickness was measured by Optical Coherence Tomography 





Jonas JB, Kreissig I et al (2003) studied 26 eyes which received an 
intravitreal injection of 25 mg of triamcinolone acetonide for diffuse diabetic 
macular oedema and followed them for 6 months. Mean visual acuity 
improved from 0.12 at baseline to a maximum of 0.19 during follow-up. 





This was compared to a control group of 16 eyes that underwent macular 




Massim P, Audren F et al (2004) injected 4mg of triamcinolone acetonide 
into one eye of twelve patients with diffuse diabetic macular oedema 
unresponsive to laser treatment, the other eye serving as a control.
6
 Central 
macular thickness on OCT improved from an average of 509µ before 
injection to 207µ at 4 weeks and 207µ at 12 weeks. In the control group 
central macular thickness was 474 pre-injection, 506µ at 4 weeks and 469µ 
at 12 weeks. At 24 weeks the oedema had recurred in all eyes and there was 
no longer a statistically significant reduction. 
 
Triamcinolone has also been used for a variety of other retinal pathologies 
including cystoid macular oedema secondary to uveitis
7
, central and branch 
retinal vein occlusions
8,9
 and the treatment of choroidal neovascular 














The pathophysiology of diabetic macular oedema is multifactorial and 
appears to have an inflammatory component. 
20
 There is a generalised 
breakdown in the blood-retinal barrier due to changes in tight junction 
proteins and leukocyte adherence to vascular endothelium, resulting in 
increased vascular permeability and accumulation of fluid in the outer 
plexiform layer of the retina - diffuse oedema. Vascular endothelial growth 
factor (VEGF) is stimulated by interleukins and other inflammatory 
mediators and has been shown to increase vascular permeability by 
phosphorylating the tight junction proteins occludin and zonula occludens-
1.
11
 The specific mechanisms by which intravitreal steroids achieve their 
effects are not entirely understood but it has been postulated that 
triamcinolone is effective in several areas to decrease oedema: Firstly, it 
decreases the activity of inflammatory mediators - interleukins 5,6 and 8, 
prostaglandins, interferon-γ and tumour necrosis factor – inhibiting VEGF 
expression and vascular permeability. Secondly, it has a positive effect on 
cellular calcium channels, aiding in the active diffusion of fluid across cells 
and therefore decreasing oedema. Thirdly, triamcinolone has been shown to 
have a generally favourable effect on the integrity of the blood-retinal 
barrier, decreasing the osmotic component of oedema.
20
   




The results of investigations into the use of intravitreal triamcinolone 
acetonide for diabetic macular oedema have been largely positive with 
significant improvements seen in visual acuity and, initially, with a 
seemingly low incidence of irreversible side effects.
4,5,6
 Further retrospective 
studies of larger numbers of injections have concluded that morbidity is, in 
fact, quite significant. The most frequent side effect has been shown to be a 
steroid-induced rise in intraocular pressure in about one third to one half of 
patients, controllable by topical pressure lowering agents in the majority of 
cases.
12
 However, irreversible steroid-induced glaucoma refractory to 
medical treatment and requiring filtration surgery is well documented.
13
 
Corticosteroid-induced glaucoma in general has, in fact, been shown to be 
irreversible in 3% and has to be managed like primary chronic open angle 
glaucoma.
14
 Endophthalmitis has been shown to occur at a rate of 0.3% per 
injection and retinal detachment, uveitis, intraocular haemorrhage and 
vascular occlusions have all been described. Formation or acceleration of 








The appropriate concentration of intravitreal triamcinolone required for 
macular oedema treatments has also been the topic of much interest. Jonas 
JB et al have published a number of papers on the topic of intravitreal 
triamcinolone using a 25mg intravitreal dosage.
4,17
 This dosage was based 
on the concentration of 0,1ml of the commercially available product and was 
continued in numerous subsequent studies by Jonas based on this arbitrary 
fact. (Personal communication). Over time, 4mg has become the generally 
accepted intravitreal dose as the therapeutic effects are noted to be 
equivalent to 25mg while possibly causing less steroid-response glaucoma.
6
 
Recently, Audren F, Lecleire-Collet A et al (2006) showed that there was no 
statistical difference at 24 weeks post intravitreal injection between 2mg and 
4mg with regard to visual acuity, central macular thickness and intraocular 
pressure, although macular oedema recurred at 16 weeks in the 2mg group 
but only at 20 weeks in the 4mg group.
15
 Lam DS, Chan CK et al (2007) in a 
randomised prospective trial studied the differences in efficacy and adverse 
effects of 4mg, 6mg and 8mg doses intravitreally.
16
 Visual acuity at 6 
months was significantly higher in the 8mg group compared to the 4mg 
group. The reduction in central macular thickness at 6 months for the 4, 6 
and 8mg groups was 28%, 42% and 60% respectively, while ocular 




hypertension occurred in 39%, 30% and 55%. These studies suggest that a 
higher dosage of triamcinolone has a longer duration of effect but may be 
associated with a higher incidence of glaucoma. At present, a 4mg, 0.1ml 
injection remains the generally accepted and most widely used intravitreal 
dosage. 
 
The benefits of intravitreal triamcinolone therapy have been noted to be 
transient in most patients, usually lasting between 4 and 6 months. A small 
group of patients appear to have a lasting response to just one injection. 
Repeated injections have been shown to effectively maintain visual and 




Sub-Tenon steroid injections are well described for a variety of ophthalmic 
conditions, including posterior uveitis and cystoid macular oedema.
18,19,20 
Their use in diabetic macular oedema is less well accepted although some 
reports in the literature show modest initial improvements in visual acuity. 
20,21
 Bakri SJ and Kaiser PK (2005) looked retrospectively at 63 eyes (73 
injections) that received 40mg of sub-Tenon triamcinolone for persistent 
clinically significant diabetic macular oedema. At 1 month 46% of eyes 
showed no change in vision and 50% showed 1 line or more improvement. 
 15 
At 3, 6 and 12 months there was a less pronounced improvement from 
baseline but without statistical significance. No OCT analysis was included 
in this paper.
20
   
 
Triamcinolone has recently been shown to enter the vitreous trans-sclerally 
by sub-Tenon injection,
 
however the same study showed the steroid 
concentration in the vitreous to be six times greater by intravitreal 
injection.
22
 Later, Thomas ER, Wang J et al (2006) showed that the vitreous 
steroid concentration attained by sub-Tenon injection can vary substantially 
in each individual, ranging from a clinically significant concentration to 
zero.
23
 These studies suggest that attaining appropriate vitreous 
concentrations of steroid are less reliable with sub-Tenon injections than 
direct placement with intravitreal injections. 
 
Peri-ocular steroid injections are not without risk and they have been 
associated with ptosis, globe perforation, retinal and choroidal vascular 
occlusions, raised intraocular pressure and cataracts.
24,25
 However, the risk 
of complication remains very low and in a retrospective review of 73 sub-
Tenon triamcinolone injections, Bakari and Kaiser (2005) found few 
complications with only a 4% incidence of ptosis at 3 months post-injection 
 16 
and in 10% a minor, transient increase in intraocular pressure that was easily 
controlled with topical hypotensive agents. Fifty percent had the 




Intravitreal injections are effective in delivering appropriate quantities of 
steroid close to the target tissue, the retina. One of the major disadvantages 
of intravitreal steroid injections for diabetic macular oedema is the 
temporary nature of the therapeutic response and the need for repeated 
injections every 4 to 6 months in most patients.
17
 The incidence of adverse 
effects in a patient requiring multiple intravitreal injections becomes far 
more significant with each injection and in this context sub-Tenon injections 
intuitively have a more favourable risk profile.  
 
At the time of commencement of the design and data collection of this study 
in 2004, there were no published reports comparing intravitreal and sub-
Tenon injections of triamcinolone acetonide. Subsequently four reports have 
been published in the peer-reviewed literature: 
 
Cardillo JA, Melo LA Jr et al (2005) conducted a prospective, double-
masked, randomized controlled trial of twelve patients (24 eyes) with 
 17 
bilateral diffuse diabetic macular oedema.
26
 One eye of each patient 
randomly received a single 4mg triamcinolone acetonide intravitreal 
injection and the fellow eye received a 40mg triamcinolone acetonide 
posterior sub-Tenon's capsule injection. They looked at visual acuity, central 
macular thickness and complications over a 6 month follow-up period and 
compared the 2 interventional arms. Significant but transient improvements 
in central macular thickness and visual acuity were found in both groups, 
although results were found to be statistically better in the intravitreal group. 
The mean central macular thickness in eyes with intravitreal injection was 
found to be significantly thinner than in the sub-Tenon's capsule-injected 
eyes at 1 month (226µ versus 431µ) and 3 months (242µ and 364µ) The 
mean visual acuity in the intravitreally injected eyes was significantly better 
than in the sub-Tenon's capsule-injected eyes at 3 months post injection (0.8 
and 1.1) Neither group were found to have any significant side effects in the 
6 month follow-up period. The authors suggested a better therapeutic result 
from intravitreal triamcinolone. This was a particularly informative result, 
despite the small study size since the two methods of injection were 




Bonini- Filho MA, Jorge R, Barbosa JC et al. (2005) looked prospectively at 
28 patients with refractory diffuse diabetic macular oedema.
27
 Patients 
randomly received 40mg sub-Tenon triamcinolone acetonide or 4mg 
intravitreally. Central macular thickness was measured by OCT and found to 
be significantly reduced in the intravitreal group at several follow-up 
intervals up to 24 weeks while there was no statistically significant decrease 
in the sub-Tenon group. Visual acuities were significantly higher in the 
intravitreal group at each time point. A significant increase in intraocular 
pressure was found in the sub-Tenon group at weeks 4 and 8 and at week 8 
in the intravitreal group. The authors concluded that intravitreal injections 
were more effective in improving central macular thickness and visual 
acuity than sub-Tenon injections. Twenty of the 28 eyes had been previously 
treated with pan retinal photocoagulation for proliferative diabetic 
retinopathy. 
 
Ozdek S, Bahceci UA et al (2006) did a retrospective analysis of 95 patients 
(126 eyes) with diffuse diabetic macular oedema refractory to argon laser 
treatment.
28
  Eighty five eyes of 60 patients had received 20mg posterior 
sub-Tenon TA and 41 eyes of 35 patients had received 4mg intravitreal TA. 
In the IVT group, 24 eyes were from a primary treatment and 17 eyes were 
 19 
from subsequent treatments. Sub-Tenon patients were followed for a mean 
of 4.1 months and IVT patients for 4.6 months. In the sub-Tenon group 
mean visual acuity improved from 0.19 to 0.22 and the mean central macular 
thickness decreased from 413µ to 312µ. In the IVT group visual acuity 
improved from 0.15 to 0.20 and central macular thickness from 494.5µ to 
288µ. The authors concluded that sub-Tenon and IVT injections were both 
effective treatments for diffuse diabetic macular oedema with IVT injections 
being more efficacious. Importantly, 20% of sub-Tenon injections were 
found to have no effect at all, supporting the Thomas ER, Wang J et al 
(2006) paper which showed that some sub-Tenon triamcinolone injections 
result in minimal or no intravitreal steroid concentration.
23
  Of note was that 
a significant rise in intraocular pressure was found in only 8.2% of the sub-
Tenon group and in 24.3% of the IVT injection group. 
 
Finally, Choi YJ, Oh IK et al (2006) did a prospective study of 60 eyes of 60 
patients with diffuse diabetic macular oedema.
29
 Each patient was assigned 
to receive a single 4mg intravitreal injection or a single 40mg posterior sub-
Tenon injection of triamcinolone acetonide. Visual acuity, intraocular 
pressure and OCT measurement of central macular thickness were recorded 
at 1 and 3 months. Both groups showed statistically significant 
 20 
improvements in visual acuity and central macular thickness from baseline 
at 1 month and 3 months after injection. The intravitreal group went from a 
baseline macular thickness of 428µ to 256µ at 1 month and 230µ at 3 
months and in the sub-Tenon group from 480µ to 318µ and 271µ. There 
were no statistically significant differences between the two groups.  In the 
intravitreal group visual acuity measured by the LogMAR system improved 
from a baseline of 0.73 to 0.57 at 1 month and 0.53 at 3 months and in the 
sub-Tenon group from 0.78 to 0.65 and 0.62. Again, there were no 
statistically significant differences between the two groups. Ten eyes (33%) 
in the intravitreal group had an intraocular pressure rise to 21mmHg or 
more, while this occurred in only 1 eye (3%) in the sub-Tenon group.  The 
authors found that the posterior sub-Tenon injection of triamcinolone 
acetonide had a comparable effect to the intravitreal injection and showed a 
lower risk of elevated IOP. They concluded that sub-Tenon injection of 
triamcinolone acetonide might be a good alternative to IVT injection for the 
treatment of diffuse diabetic macular oedema. They also conceded that their 
results might have been good because the macular oedema was not 
refractory at baseline. 
 
 21 
This study is a prospective, interventional case series to investigate the use 
of triamcinolone acetonide in the treatment of patients in the Durban 
metropolitan area of KwaZulu-Natal, South Africa, with diffuse diabetic 
macular oedema refractory to conventional laser therapy. The drug was 
made available through Visicare as Kenacort (Bristol Meyers Squibb). Each 
millilitre contains 40mg triamcinolone acetonide with sodium chloride, 
0.99% benzyl alcohol preservative, 0.75% carboxymethylcellulose sodium 
and 0.04% polysorbate 80. 
 
How efficacious is intravitreal and sub-Tenon triamcinolone acetonide for 
the treatment of diffuse diabetic macular oedema in our patient population 
with respect to macular thickness and visual acuity?  What is the incidence 
of complication of these interventions? How do these two modes of delivery 









Materials and methods 
 
A prospective, randomised comparative study was undertaken. The study 
had approval from the Ethics Committee of the Nelson R Mandela School of 
Medicine. 
 
Nineteen patients with symptomatic, clinically significant diffuse diabetic 
macular oedema based on assessment by fundoscopy with a 90 dioptre lens 
and showing no response to two or more macular grid laser therapies were 
included in the study. Patients excluded from the study: Those with pre-
existing glaucoma or ocular hypertension, known steroid responders, 
concomitant macular pathology affecting visual acuity, macular ischaemia, 
an unclear fundal view (e.g. significant cataract, vitreous haemorrhage) and 
proliferative diabetic retinopathy or severe non-proliferative diabetic 






• Diffuse diabetic macular oedema - 2 previous    




• Pre-existing glaucoma/ocular hypertension  
  
• Steroid responders 
  
• Poor fundal view 
  
• Macular ischaemia (FFA) 
  
• Other macular pathology causing low VA 
  
• Cataract surgery within the last 6 months 
  
• Severe non-proliferative diabetic retinopathy  
   or proliferative diabetic retinopathy 
  
  
Table I – Study inclusion and exclusion criteria. 
 
After obtaining written consent, patients underwent fluorescein fundal 
angiography to exclude macular ischaemia as a cause of reduced visual 
acuity. A proforma with demographic and clinical information (age, sex, 
race, diabetic history etc) was completed. Patients were examined with 
respect to their visual acuity, as measured by logarithm of minimal angle of 
resolution (Logmar) test, intraocular pressure and macular thickness by 
optical coherence tomography (OCT – Zeiss-Humphrey instruments, San 
 24 
Leandro, California) measurement. OCT examinations consisted of six 
radial cuts centred on the fovea. The central macular thickness was taken as 
the 1000µ circle centred on the foveola and was automatically calculated by 
the OCT software.  
 
Patients’ eyes were then alternately assigned to two experimental groups. 
Eyes assigned to group A received a single pars plana intravitreal injection 
of 4mg triamcinolone acetonide in the eye clinic by conventional sterile 






























The intravitreal injection technique: 
The injection was preceded by softening of the globe by gentle massage. The 
eye was anaesthetised with topical benoxinate and sterilised with 5% 
povidone iodine into the conjunctival sac. The periorbital area was cleaned 
with a betadine solution followed by sterile draping of the head and neck and 
the use of a sterile wire speculum to keep the lids open and the eyelashes 
away from the injection site. A sterile cotton tipped applicator soaked in 
benoxinate was applied to the injection site for 5 minutes and the injection 
site was identified with a calliper - 4mm posterior to the limbus in phakic 
patients and 3.5mm in pseudophakic patients. Thereafter, 4mg (0.1ml) of 
triamcinolone acetonide (Kenacort, Bristol Myers Squibb) was injected via 
the pars plana, posterior to the superior limbus. Patients then received one 
drop of chloramphenicol immediately after the procedure and four times 
daily for the following 5 days. Correct placement of the steroid and normal 
retinal arterial circulation was confirmed on indirect fundoscopy.  
 
The sub-Tenon injection technique: 
Benoxinate drops were used to anaesthetise the eye and 5% povidone iodine 
was instilled into the conjunctival sac. The periorbital area was cleaned with 
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a betadine solution followed by sterile draping of the head and neck and the 
use of a sterile wire speculum to keep the lids open. A small bleb of 
lignocaine was injected inferonasally under the conjunctiva and a cut-down 
made with Westcott scissors through conjunctiva and Tenon’s capsule to 
bare sclera, 8mm posterior to the limbus. Forty milligrams (1ml) of 
triamcinolone acetonide (Kenacort) was injected into the sub-Tenon's space 
using an olive-tipped canula, with particular attention to avoiding reflux of 
steroid. 
 
Follow up examinations were done at day 1, 2 weeks, 6 weeks, 12 weeks, 24 
weeks and 36 weeks after injection. At each visit visual acuity, macular 
thickness by OCT scan, intraocular pressure and complications arising from 
the intervention were recorded, as well as a clinical evaluation of the macula 
and optic disc by fundoscopy. Appropriate intraocular pressure lowering 
measures were undertaken if there was any clinically significant rise in 
intraocular pressure.  
 







Twenty nine eyes of 22 patients were initially enrolled in the study. Fifteen 
eyes received intravitreal triamcinolone and 14 eyes received sub-Tenon 
injections. One patient absconded after the 6 week follow up visit (2 study 
eyes), one patient died of renal failure after the 6 week follow up (2 study 
eyes) and one patient died of cardiac disease after the 6 week follow up (1 
study eye). Thus 24 eyes of 19 patients were followed for 6 to 9 months post 
injection with 13 eyes in the intravitreal group and 11 eyes in the sub-Tenon 
group. 
 
There were no statistically significant differences between the two groups at 
baseline in terms of patient macular thickness as measured by OCT 




Table III - Independent Samples Test – comparing macular thickness and visual acuity 
at baseline between the 2 treatment groups.   
For OCT p=0.914 and for VA p=0.459, therefore no significant differences between the 




Eighteen patients were Indian, 3 African, and 1 Coloured. The mean patient 
age was 65 (range 52 to 80). All patients had type 2, non-insulin dependent 
diabetes mellitus. Macular oedema was present in all patients for at least two 
years and was considered longstanding and refractory to treatment. 
 
The mean central macular thickness at baseline in the intravitreal group was 
458µ. Macular thickness at the follow up intervals was 368 (n=14), 370 
(n=14), 408 (n=13), 512 (n=13) and 508 (n=10) at 2, 6, 12, 24 and 36 weeks 
post-injection respectively. Mean visual acuity at the follow up intervals was 
0.764 at baseline and 0.68, 0.66, 0.60, 0.70 and 0.88 at 2, 6, 12, 24 and 36 
weeks post-injection respectively.  The mean central macular thickness at 
   
Levene's Test for 
Equality of 
Variances 
t-test for Equality of Means 





95% Confidence Interval of 
the Difference 
                  Lower Upper 
OCT  
Equal variances  
assumed 
.232 .634 .109 23 .914 7.96 73.322 -143.717 159.640 
  
Equal variances  
not assumed 
    .107 20.744 .915 7.96 74.088 -146.229 162.152 
VA  
Equal variances  
assumed 
.083 .776 .754 23 .459 .0929 .12335 -.16222 .34812 
  
Equal variances  
not assumed 
    .764 21.673 .453 .0929 .12168 -.15962 .34552 
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baseline in the sub-Tenon group was 450µ. At follow up macular thickness 
was 480 (n=14), 462 (n=12), 530 (n=10), 563 (n=11) and 471 (n=7) at 2, 6, 
12, 24 and 36 weeks post-injection respectively. Mean visual acuity was 
0.66 at baseline and on follow up, 0.70, 0.72, 0.64, 0.78 and 0.80 at 2, 6, 12, 
24 and 36 weeks post-injection respectively. There were statistically no 
significant differences between the changes in mean value for macular 
thickness or visual acuity between the intravitreal and sub-Tenon groups 


















458 368 370 408 512 508 
No. of eyes: 14 14 14 13 13 10 
 
Table IV - Changes in macular thickness after intravitreal triamcinolone 
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450 480 462 530 563 471 
No. of eyes: 15 14 12 10 11 7 
 
Table V - Changes in macular thickness after sub-Tenon triamcinolone 
 
In the intravitreal group 9 of the 13 eyes that were followed to 6 months had 
a rise in intraocular pressure above 21mmHg. In 1 eye this was above 
30mmHg. Four eyes (31%) required pressure lowering treatment. In 2 eyes, 
1 topical pressure lowering drop was needed and in 2 eyes 2 medications 
were needed. In the sub-Tenon group, 3 of the 13 eyes that were followed to 
6 months had a rise in intraocular pressure above 21mmHg with only 1 eye 
(8%) requiring 1 topical medication. In both groups, pressures returned to 
normal by 6 months and all drops were discontinued. 
 
There were no other significant adverse events in either group. 
    
 31 
Macular thickness 





Change in thickness from baseline: 
Baseline:  458µ   
Week 2:  368µ 20% decrease  
Week 6:  370µ 26% decrease 
Week 12: 408µ 11% decrease 
Week 24: 512µ 12% increase 
Week 36: 508µ 11% increase 
 





Visual Acuity (LogMAR) 
 Intravitreal group  
Baseline:  0.76   
Week 2:  0.68 Gained 4 letters  
Week 6:  0.66 Gained 5 letters  
Week 12: 0.6 Gained 8 letters  
Week 24: 0.7 Gained 3 letters 
Week 36: 0.88 Lost 6 letters   
 









Change in thickness from baseline: 
 
Baseline:  450µ   
Week 2:  480µ 7% increase  
Week 6:  462µ 3% increase 
Week 12: 530µ 18% increase 
Week 24: 563µ 25% increase 
Week 36: 471µ 5% increase 
 




Visual Acuity (LogMar) 
Sub-Tenon Group 
Baseline:  0.66   
Week 2:  0.70 Lost 2 letters  
Week 6:  0.72 Lost 3 letters  
Week 12: 0.64 Gained 1 letters  
Week 24: 0.78 Lost 6 letters 
Week 36: 0.80 Lost 7 letters   
 















































































Intravitreal - Week 2 
 
 
Intravitreal - Week 6
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Intravitreal - Week 12
 
Intravitreal - Week 24
 
Intravitreal - Week 36
 
 
Figure 4 - OCT map of macular thickness – intravitreal triamcinolone 
acetonide. Macular thickness reduced after triamcinolone injection at weeks 





























Figure 5 - OCT map of macular thickness – sub-Tenon triamcinolone 
acetonide. Macular thickness does not reduce after triamcinolone injection. 
Progressively worsens over the follow-up period.                                                                             
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Figure 7: Optical coherence tomography image – oedema resolved 6 weeks 






In this study, intravitreal triamcinolone for longstanding diffuse diabetic 
macular oedema refractory to laser treatment resulted in a small and 
transient but clinically significant improvement in visual acuity and central 
macular thickness. It was superior to sub-Tenon injections which had no 
apparent effect on macular thickness or visual acuity. Neither intervention 
was found to have any serious adverse side effects over the 9 month follow-
up period. A modest increase in intraocular pressure, seen with greater 
frequency in the intravitreal group, was transient and well controlled with 
topical medications. 
 
There were no statistically significant differences between the sub-Tenon 
and intravitreal groups but the improvements in macular thickness and visual 
acuity in the intravitreal group were clinically superior 
 
In the intravitreal group there was a modest decrease in macular thickness 
for the first 12 weeks post-injection – to a maximum mean decrease of 26% 
at week 6. A modest temporary improvement in visual acuity was also seen 
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for the first six months - with a maximum mean improvement of 8 letters 
(1.5 Snellen lines) at week 12.  By week 24 the macular oedema had 
recurred. Martidis et al
5
 reported 55%, 58% and 38% reductions in mean 
macular thickness at 1, 3 and 6 months follow up in their groundbreaking 
intravitreal triamcinolone study. They also saw a mean improvement of 2.5 
Snellen lines at 1 and 3 months. Massin et al
6
 reported similar transient 
reductions in central macular thickness with macular oedema recurring by 
week 24. Jonas et al
4
 reported a mean visual acuity improvement from 0.12 
at baseline to a maximum of 0.19 during follow-up. 
 
In this study, therefore, the transient improvements in visual acuity and 
central macular thickness seen with intravitreal injections, although far more 
modest, reflect findings from previous studies of intravitreal triamcinolone 
injections for refractory diffuse diabetic macular oedema. There is a clear 
trend towards an initial improvement in visual acuity and a reduction in 
central macular thickness, followed by recurrence of oedema and 
deterioration in visual acuity by 6 months post-injection. 
 





In the sub-Tenon group there was no mean improvement in macular 
thickness in the 9 months following injection and this did not clinically 
appear to be a useful intervention. In fact, there was a mean loss of visual 
acuity at each time point, except at week 12 where there was a gain of just 1 
letter. In contrast, Bakri and Kaiser
20
 reported improvements in visual acuity 
from a mean baseline of 20/80 to 20/50 at 1 month, stabilizing to 20/65 at 3 
months, 20/68 at 6 months and 20/63 at 12 months. OCT was not performed 
in this study.  There do not appear to be any other studies in the literature 
looking at the effect of posterior sub-Tenon injections for diffuse diabetic 
macular oedema alone.  
 
 
Four previous studies have looked at the difference between the effect and 














Decreased central macular thickness/improved visual acuity             IVT = intravitreal 
Increased central macular thickness/worse visual acuity                    ST = sub-Tenon 
 
Table X – A comparison of the results of the 4 previous intravitreal versus 
sub-Tenon injection studies. 
 
In all four studies, the reductions in central macular thickness with 
intravitreal injections are comparable to the results of Martidis and Duker
5
. 
In this study a trend towards improvement was seen but was far less 
impressive than the previous four studies. Reported improvements in visual 
acuity were reasonably modest. Cardillo, Melo et al
26
 reported a maximum 
mean improvement in visual acuity of 12 letters (2.5 Snellen lines) at 3 
months. Bonini-Filho, Jorge et al
27
 reported a maximum of 10 letters (2 





Cardillo, Melo et al 
Bonini-Filho, Jorge et 
al Ozdek, Bahceci et al Choi, Oh et al Zaborowski 
IVT ST IVT ST IVT ST IVT ST IVT ST 
Central macular 
thickness (%)   
1 month 56 16 41 6 40 18 41 34 26 3 
3 months 53 29 31 5 42 24 46 44 11 18 
6 months 15 16 23 0 25 25     12 25 
Visual acuity 
(letters)   
1 month 7 1 10 6 3 1 8 7 5 3 
3 months 12 0 5 0 3 0 10 8 8 1 
6 months 2 0 0 0 0 0     3 6 
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Snellen lines) at 1 month. Choi, Oh et al
29
 reported a maximum of 10 letters 
(2 Snellen lines) at 3 months.  Ozdek, Bahceci et al
28
 had the least 
impressive improvements reporting a 3 letter improvement at 1 and 3 
months.  
 
In this study, the visual acuity improvements with intravitreal injections 
were surprisingly good and comparable to the 4 previous studies despite the 
unimpressive reductions in central macular thickness. A 5 letter 
improvement was found at 1 month (1 Snellen line) and an 8 letter 
improvement (1.5 Snellen lines) was found at 3 months. 
 
With sub-Tenon injections, Cardillo, Melo et al and Ozdek, Bahceci et al 
reported no real improvement in mean visual acuity, while Bonini-Filho, 
Jorge et al reported a 6 letter improvement at 1month and Choi, Oh et al 
reported 7 letters at 1 month and 8 letters at 3 months.  
Cardillo, Melo et al, Ozdek, Bahceci et al and Choi, Oh et al all reported 
improvements in central macular thickness which were statistically inferior 
to the intravitreal injections. Bonini-Filho, Jorge et al found no improvement 
from baseline. 





In this study, sub-Tenon’s injections were more in keeping with the results 
of Bonini-Filho et al and there was no significant mean improvement in 
central macular thickness or visual acuity. 
 
Choi, Oh et al found that there was statistically no difference between the 
sub-Tenon and intravitreal groups. Sub-Tenon injections were considered a 
good and safer alternative to intravitreal injections. Their patients differed 
from other studies in that the diffuse diabetic macular oedema was not 
refractory. Cardillo, Melo et al concluded that there was a clear short-term 
trend favouring intravitreal injection although both interventions had a 
favourable transient benefit. Ozdek, Bahceci et al found a pronounced effect 
with intravitreal injections and less effective but significant benefits with 
posterior sub-Tenon’s. Bonini-Filho, Jorge et al found significant benefits 
with intravitreal steroid but not with sub-Tenon injections. They believed 
that triamcinolone reflux might be partly to blame for the poorer sub-Tenon 
results, as well as an inadequate positioning of the steroid next to the 
macular area. They felt that the sclera and choroid acted as a significant 
barrier to triamcinolone diffusion into the vitreous.  
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There are several possible explanations for the poor results in this study: 
1. The group of patients studied in the Department of Ophthalmology of 
the University of KwaZulu-Natal have notoriously poor metabolic and 
hypertensive control. There may actually be degrees of treatment 
resistance with diabetic macular oedema and these metabolic factors 
may limit the efficacy of steroid treatment. Metabolic factors were not 
quantified but may warrant further study as to their role in the efficacy 
of steroid treatment. A subsequent study might exclude patients with 
poor glycaemic and blood pressure control. 
2. All the studied patients had diabetic macular oedema for at least 2 
years and in many cases for much longer. Again, there might be 
degrees of treatment resistance in diabetic macular oedema and the 
duration of oedema may play a role in the sensitivity to steroid 
treatment. 
3. There was a definite study bias towards a more severe, refractory 
disease. Referred patients from fellow clinicians to the study project 
typically had profound macular oedema and did not necessarily 
represent the typical patient population of diabetics with macular 
oedema refractory to 2 macular grid laser treatments.  
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Unlike the 4 previous studies comparing intravitreal and sub-Tenon 
injections, this study continued to 9 months of follow up in most patients. 
An interesting finding was that at 9 months, central macular thickness and 






Central macular thickness 

















This suggests the interesting possibility of a steroid withdrawal, rebound 
type effect. No study has yet looked at the 9 month outcome of patients who 
were treated with triamcinolone acetonide injections but not re-treated. This 
data is suggestive of a deleterious effect of once-off triamcinolone injections 
and may support continued injections for the recurrence of oedema. The 
possibility of a steroid withdrawal, rebound effect warrants further study. 
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Most previous studies have shown either very poor efficacy with sub-Tenon 
triamcinolone as a treatment for diffuse diabetic macular oedema or modest 
benefits statistically inferior to intravitreal injections. The results of this 
study do not support the use of sub-Tenon triamcinolone acetonide for 
longstanding diffuse diabetic macular oedema refractory to laser treatment. 
Why is intravitreal delivery apparently more effective than sub-Tenon?  
The most likely reason is poor localisation of steroid adjacent to the macula 
due to reflux or poor injection technique. Intravitreal injections deliver a 
very predictable dose of steroid into the vitreous but it is unpredictable with 
sub-Tenon injections. This was seen experimentally by Thomas ER, Wang J 
et al (2006)
23
 where sub-Tenon injections of triamcinolone produced a wide 
variety of vitreous steroid concentrations ranging from levels comparable to 
intravitreal injections to no detectable steroid at all. On average, the vitreous 
concentration with sub-Tenon injections was much lower than with 
intravitreal injections. There is certainly a degree of technical skill in 
ensuring that the full 40mg bolus of steroid is successfully delivered sub-
Tenon and adjacent to the macula. Intravitreal injections are technically 
simple and there is little doubt about the ease of achieving a high 
concentration of the drug in the vitreous. Intuitively one also feels that the 
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sclera and choroid pose a natural barrier to diffusion of the steroid into the 
vitreous. This is overcome to a degree by injecting ten times the intravitreal 
dose in sub-Tenon’s injections. 
 
One of the main outcome measures of this study was to report any adverse 
effects of the triamcinolone treatments. In both study groups there were no 
major adverse effects although there was a rise in intraocular pressure above 
21mmHg in 9 of the 13 eyes in the intravitreal group. In 4 eyes (31%) 
topical pressure lowering treatment was required. In the sub-Tenon group, 3 
of 11 had a rise in intraocular pressure above 21mmHg with only 1 eye (8%) 
requiring topical medication. In both groups, pressure lowering was 
successful and pressures returned to normal by 6 months with all drops 
discontinued. The increased frequency of ocular hypertension in the 
intravitreal group would be expected if intravitreal injections caused a higher 
intraocular concentration of steroid. In a meta-analysis of 272 patients who 
received 20mg intravitreal injections, 41.2% had pressures >21mmHg, 
11.4% >30mmHg, 5.5% >35mmHg and 1.8% >40mmHg. 
 
The effect of the steroid on cataract formation was not specifically studied 
but posterior sub-capsular cataracts are a well-recognised complication and 
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were shown to have a prevalence of 45% after 1 year after a single 4mg 
intravitreal injection of triamcinolone.
30
 No endophthalmitis, sterile or 
infective, was encountered although the study size was small and other 
studies have found the incidence of infective endophthalmitis to be up to 
























The results of this study should be viewed with caution as the study size was 
small with a large number lost to follow up. Patient eyes were alternately 
assigned to either treatment arm and therefore this was not a randomised 
controlled study allowing potential selection bias. 
 
Triamcinolone acetonide appears to be of limited value in the treatment of 
longstanding diabetic macular oedema refractory to laser treatment. While 
intravitreal injections showed a clinically significant trend towards a 
transient improvement in visual acuity and central macular thickness, this 
effect was modest. Sub-Tenon injections had no effect on visual acuity or 
central macular thickness. Intravitreal injections appear to be more effective 
than sub-Tenon injections, probably due to a more predictable delivery of 
steroid into the vitreous. The results of this study do not support the use of 
sub-Tenon injections for longstanding, refractory disease. 
 
Poor clinical results may be due to permanent damage to the retinal pigment 
epithelium and photoreceptors due to disease chronicity, making 
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improvements in visual acuity modest at best. The macular oedema may also 
become more refractory with time. Intravitreal triamcinolone may be more 
effective earlier in the disease process. Poor metabolic control may play a 
role in a weak response to steroid treatment.  
 
Once the decision has been made to treat, the clinician should be prepared to 
repeat injections if and when oedema returns. Single injections may actually 
worsen the disease in the long-term, possibly through a rebound-type effect 
of steroid withdrawal and should be used with caution. This effect warrants 
further study. 
 
Single injections of sub-Tenon and intravitreal triamcinolone for diffuse 
diabetic macular oedema refractory to laser are relatively safe short to 
medium term, but patients will probably require management of secondary 
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